Coronavirus [COVID-19] – PHEIC


Coronavirus [COVID-19]
Public Health Emergency of International Concern (PHEIC)

Situation report – 208
Coronavirus disease 2019 (COVID-19)
15 August 2020

Confirmed cases :: 21 026 758 [week ago: 19 187 943 ]
Confirmed deaths :: 755 786 [week ago: 716 075]

Highlights [selected]
:: The International Narcotics Control Board, World Health Organization, and the United Nations Office on Drugs and Crime have released a statement calling on governments to ensure that the procurement and supply of controlled medicines in countries meet the needs of patients, both those who have COVID-19 and those who require internationally controlled medicines for other medical conditions.

:: While several countries i n the Americas have implemented innovative strategies to boost immunization programmes during the COVID-19 pandemic, concerns about risk of exposure, as well as challenges accessing services during lockdown, have led to a reduction in vaccination coverage. This was shown in a series of surveys carried out by the WHO Regional Office for the Americas.

:: Africa is marking six months since the first cases of COVID-19 were detected on the continent. Cases have been gradually increasing, with South Africa bearing the brunt of the crisis, with over hal f a mi l lion cases and 11 000 deaths


COVID-19 Vaccines – Access/Procurement/Supply

CEPI reserves manufacturing capacity for COVID-19 vaccines at SK bioscience
13 Aug 2020
:: Vaccine manufacturing capacity in 2020 and 2021 has been reserved for vaccines designated by CEPI.
:: Reserved manufacturing capacity at SK bioscience will support COVAX goal to produce 2 billion doses of safe and effective vaccine by the end of 2021.
August 13 2020, Oslo, Norway– An agreement between CEPI and SK bioscience Co. Ltd. (SK bioscience) has secured capacity to manufacture COVID-19 vaccines at SK bioscience’s facilities in South Korea, supporting the goal of CEPI and its COVAX partners to produce 2 billion doses of safe and effective vaccine by the end of 2021.
Under the terms of the agreement, SK bioscience will reserve manufacturing capacity in 2020 and 2021 exclusively for the development and production of COVID-19 vaccines designated by CEPI. CEPI has an option to extend the reservation of manufacturing capacity beyond 2021, should it be needed…